Ignite Creation Date:
2025-12-25 @ 2:37 AM
Ignite Modification Date:
2025-12-31 @ 10:17 AM
Study NCT ID:
NCT01465334
Status:
TERMINATED
Last Update Posted:
2023-08-29
First Post:
2011-10-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Sponsor:
Dana-Farber Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-12
Start Date Type:
ACTUAL
Primary Completion Date:
2014-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-01
Completion Date Type:
ACTUAL
First Submit Date:
2011-10-18
First Submit QC Date:
None
Study First Post Date:
2011-11-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-05-16
Results First Submit QC Date:
None
Results First Post Date:
2019-06-26
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-08-28
Last Update Post Date:
2023-08-29
Last Update Post Date Type:
ACTUAL